P/E ratio for Seelos Therapeutics (SEEL)
P/E ratio as of May 2024 (TTM): -0.4262
According to Seelos Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.426232. At the end of 2022 the company had a P/E ratio of -1.00.
P/E ratio history for Seelos Therapeutics from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.00 | -52.76% |
| 2021 | -2.12 | -41.05% |
| 2020 | -3.59 | 1097.86% |
| 2019 | -0.2998 | -21.21% |
| 2018 | -0.3805 | -108% |
| 2017 | 4.75 | -527.94% |
| 2016 | -1.11 | -57.8% |
| 2015 | -2.63 | 36.91% |
| 2014 | -1.92 | -62.99% |
| 2013 | -5.20 | 208.11% |
| 2012 | -1.69 | -70.59% |
| 2011 | -5.73 | 336.64% |
| 2010 | -1.31 | 62.7% |
| 2009 | -0.8070 | -65.41% |
| 2008 | -2.33 | -81.92% |
| 2007 | -12.9 | 150.47% |
| 2006 | -5.15 | 120.88% |
| 2005 | -2.33 | -39.33% |
| 2004 | -3.85 | -40.24% |
| 2003 | -6.44 | 833.6% |
| 2002 | -0.6893 | -87.02% |
| 2001 | -5.31 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -4.41 | 934.24% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.